Next pivotal event for DNDN

Tomorrow (April 28) at 12:20 pm Pacific time, Dendreon will present detailed results of Phase III clinical trials for Provenge, a prostate cancer immunotherapy.

Shares of DNDN tripled April 14, when CEO Mitchell Gold presented "unambiguous" top-line results that Provenge met its 22% primary endpoint survival benefit above the placebo control group.

Mike Huckman of CNBC is preparing several updates and interviews from Dr. Gold at the American Urological Association conference in Chicago. A "clear hit" as quoted by Dr. Gold two weeks ago, could cause shares of DNDN to soar even more. A disappointing result could cause shares to tank. Given his positive, upbeat announcement, while offering no metrics, I would be surprised if the survival benefit guideline was not surpassed by a wide margin, as that would invite shareholder lawsuits.

http://www.cnbc.com/id/30389525

Notice Huckman's comment on shares possibly being halted again. This could potentially be music to those long on the shares, as that occurred April 14 in pre-market trading, when the shorts got squeezed. Look for fireworks tomorrow.